Determination of serum tumor markers TPS and CA 15-3 during monitoring of treatment in metastatic breast cancer patients

Anticancer Research

Volumn 16, Issue 4 B, 1996, Pages 2169-2172

  Schuurman, J J ^a   Bong, S B ^a   Einarsson, R ^b  

^a MARTINI HOSPITAL   (Netherlands)

^b BEKI Diagnostics AB   (Sweden)

Author keywords

CA 15 3; Metastatic breast cancer; TPS; Treatment monitoring

Indexed keywords

CA 15-3 ANTIGEN; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST METASTASIS; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; MONITORING; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CA-15-3 ANTIGEN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PEPTIDES; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 0029833051     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Merimsky O, Inbar M, Harenvein M et al: Serial serum measurement in the follow-up of breast cancer patients. Eur J Cancer 27: 1440-1444, 1991.
2. Robertson JFR, Pearson D, Price MR, Selby C, Blarney RW and Howel A: Objective measurement of therapeutic response in breast cancer using tumor markers. Br J Cancer 64: 757-763, 1991.
3. Nicolini A, Colombini C, Luciani L et al: : Evolution of serum CA 15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients. Br J Cancer 64: 154-158, 1991.
4. Rydlander L, Ziegler E, Bergman T, Schoberl E, Steiner G, Zetterberg A, Marberger M, Bjorklund P, Skern T, Einarson R and Jornvall U: Molecular characterization of tissue polypeptide antigen specific epitope (TPS); Relationship to human cytokeratin 18. J Biol Chem 1996, Submitted for publication.
5. Bjorklund B: Tumor markers TPA, TPA-S and cylukeratins. Tumordiagn 13: 78-80, 1992.
6. Devine PL, McGuckin MA, Quin RJ, and Ward BG: Predictive value of the combination of serum markers. CA 125, CASA and TPS in ovarian cancer. Int J Gynecol Cancer 5: 170-178, 1995.
7. Einarsson R: TPS-A cytokeratin marker for therapy control in breast cancer, Scand J Clin Lab Invest 55 (Suppl 221): 113-115, 1995.
8. van Dalen A, Heering KJ, Barak V et al: Treatment response in metastatic breast cancer. A multicenter study comparing UICC criteria and tumor marker changes. The Breast 1996, In press.
9. Kornek G, Schenk T, Radercr M, Djavarnmad M, and Scheithauer W: Tissue polypeptide-specific antigen (TPS) in monitoring palliative treatment response of patients with gastrointestinal tumours. Br J Cancer 71: 182-185, 1995.
10. Tarle M: Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer. Anticancer Res 13: 769-778, 1993.
11. van der Gaast A, Schoenmakers CHH, Kok TC, Blijenberg BG, Hop WCJ and Splinter TAW: Prognostic significance of tissue polypeptide-specific antigen (TPS) in patients with advanced non-small cell lung cancer. Eur J Cancer 304: 1783-1786, 1994.
12. Haywoardt JL, Carbone PP, Heuson J-C, Kumaoka S, Segaloff A and Rubens RD: Assessment of response to therapy in advanced breast cancer. Eur J Cancer 13: 89-94, 1977.
13. Ng JSY, Sturgeon C, Seth J, Paterson GM, Roulston JE and Leonard RFC: Serological markers for metastatic breast cancer. Disease markers 11: 217-223, 1993.
14. van Dalen A, van der Linde DL, Heering KJ and Blusse van Oudalblas A: How can treatment response be measured in breast cancer patients? Anticancer Res 13: 1901-1904, 1993.